Elucidation of Signal Networks to Stress in Renal Cell Carcinoma by Proteomic Analysis
| Project/Area Number |
22591775
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAO Masahiro 横浜市立大学, 医学研究科, 准教授 (00260787)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | ストレス / プロテオミクス / 腎細胞癌 / プロテオミクス解析 / ストレス対応 / 情報伝達系 / 腎癌 / ストレス負荷 / バイオマーカー |
|---|
| Research Abstract |
We found some intracellular molecules in human renal cell carcinoma(RCC) cells which expressed or activated by hypoxia conditions using proteome analyses. These molecules were thought to act critical roles in the intracellular signal pathways to gain the resistance to tyrosine kinase inhibitors (TKI) targeting angiogenesis, which were mainstay of treatment for human RCC. One of these molecules acts to regulate glucoseuptake, and glucose uptake was speculated to be the index to resistance to TKI treatment. Actually, we found that the uptake of glucose in human RCC evaluated by FDG PET/CT could predict the response of RCC to TKI treatment.
|
Report
(4 results)
Research Products
(29 results)
-
-
[Journal Article] Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.2012
Author(s)
Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, Sano F, Murakami T, Kishida T, Miura T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Inoue T, Kubota Y, Nakaigawa N
-
Journal Title
BMC Cancer
Volume: 12
Issue: 1
Pages: 162-162
DOI
Related Report
Peer Reviewed
-
[Journal Article] C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy2012
Author(s)
Ito H, Shioi K, Murakami T, Takizawa A, Sano F, Kawahara T, Mizuno N, Makiyama K, Nakaigawa N, Kishida T, Miura T, Kubota Y, Yao M.
-
Journal Title
BMC Cancer
Volume: 12
Issue: 1
Pages: 337-337
DOI
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.2011
Author(s)
Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, Yoneda M, Inamori M, Nakamura F, Ishiguro H, Nakaigawa N, Nagashima Y, Taguri M, Kubota Y, Goshima Y, Morita S, Endo I, Maeda S, Nakajima A, Nakagama H
-
Journal Title
Cancer Sci
Volume: 102(11)
Pages: 2029-37
NAID
Related Report
Peer Reviewed
-
-
-
[Journal Article] Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report2010
Author(s)
Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N
-
Journal Title
BMC Cancer
Volume: 10
Issue: 1
Pages: 667-667
DOI
Related Report
Peer Reviewed
-
[Journal Article] Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT2010
Author(s)
Minamimoto R, Nakaigawa N, Tateishi U, Suzuki A, Shizukuishi K, Kishida T, Miura T, Makiyama K, Yao M, Kubota Y, Inoue T
-
Journal Title
Clin Nucl Med
Volume: 35(12)
Issue: 12
Pages: 918-23
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
